NCT07189403View on ClinicalTrials.gov

A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

March 1, 2028

Study Completion Date

March 1, 2028

Conditions
Advanced or Metastatic Adrenocortical CarcinomaMetastatic Castration-resistant Prostate Cancer
Interventions
DRUG

DS9051b

Administered orally

Trial Locations (6)

10032

Research Site, New York

31100

Research Site, Toulouse

34232

Research Site, Sarasota

94800

Research Site, Villejuif

02903

Research Site, Providence

SW3 6JJ

Research Site, London

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT07189403 - A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer | Biotech Hunter | Biotech Hunter